Oscar Health, Inc. (OSCR) · Nov 5, 2026 · Earnings

Oscar Health earnings beat as 2026 outlook rises again

Beat — Diluted EPS $0.49 vs approximately $0.14 loss consensus

Oscar Health’s Q3 earnings beat expectations, with sharply improved margins and a third 2026 operating-earnings outlook raise.

Oscar is an ACA-focused health insurer scaling membership while trying to prove that its pricing discipline can convert growth into durable profits. The prior story already included a strong first half and a higher 2026 outlook, so this filing is not a first proof of profitability—but it materially extends that progress. The broader ACA backdrop is becoming more demanding as subsidy changes pressure affordability and enrollment, making execution and risk selection more important.

The quarter was far ahead of the published bar. Oscar produced $0.49 of diluted EPS against a published consensus near a $0.14 loss, while revenue reached $5.14 billion versus roughly $4.69 billion expected. The operating swing was substantial: earnings from operations rose to $178.0 million from a $129.3 million loss a year earlier, and adjusted EBITDA reached $206.9 million from negative $101.5 million.

MetricQ3 2026Q3 2025Consensus / prior outlook
Total revenue (Financial Highlights)$5.14B (+72.1%)$2.99B~$4.69B
Diluted EPS (Income Statement)$0.49$(0.53)~$(0.14)
Medical loss ratio (Financial Highlights)84.0% (-4.5 pts)88.5%
SG&A expense ratio (Financial Highlights)14.0% (-3.5 pts)17.5%
Earnings from operations (Financial Highlights)$178.0M$(129.3M)
FY26 earnings from operations outlook (Guidance Summary)$850M–$950M$600M–$800M

The quality of the improvement is mostly operational, but risk adjustment helped. The medical loss ratio fell to 84.0% from 88.5%, and SG&A fell to 14.0% from 17.5%, showing better pricing and cost leverage. Oscar also disclosed a $250 million revenue benefit from updated risk-adjustment estimates and $42 million of favorable prior-period development, so the quarter was not entirely a clean recurring run-rate.

Management raised the full-year bar for the third time, making the change more important than a one-quarter beat. Revenue guidance moved to $19.0–$19.3 billion from $18.7–$19.0 billion, while operating-earnings guidance rose to $850–$950 million from $600–$800 million. The improved MLR and SG&A ranges imply that management expects the better economics to carry through the year rather than treating Q3 as an isolated result.

Growth is still substantial, but the next test is whether these margins survive the 2027 ACA reset. Effectuated membership reached 2.69 million, up from 2.12 million a year earlier, while the company is entering a more volatile enrollment environment as subsidy and eligibility changes reshape the individual market. That makes the third guidance raise a meaningful upgrade to the current story, but not yet proof that 2026’s unusually favorable risk-adjustment and underwriting conditions will fully repeat. 〔0〕

Bottom line: This is a clear upgrade to Oscar’s operating story: the company beat a low profitability expectation and raised guidance materially again. The main qualification is that risk-adjustment gains contributed meaningfully, so 2027 execution will determine how durable the margin improvement is.

What to watch next

2027 ACA enrollment and pricing results

Original filing on SEC EDGAR

More Oscar Health, Inc. news

Oscar Health earnings beat as 2026 outlook rises again | OSCR Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.